|
Oct
23 2010
--
Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial ResultsOriginally posted in Cystic Fibrosis News From Medical News Today Pharmaceutical company Pharmaxis (ASX: PXS) announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first time at the North American Cystic Fibrosis Conference (NACFC) currently underway in Baltimore…
Oct
22 2010
--
ARIKACE™ Demonstrates Sustained Benefit In Multiple Studies And Over Multiple Cycles Of Treatment Of Pseudomonas Lung InfectionsOriginally posted in Cystic Fibrosis News From Medical News Today Transave, Inc., reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections…
Oct
20 2010
--
Baltimore To Host Largest Gathering Of Cystic Fibrosis Scientists And Clinicians In The WorldOriginally posted in Cystic Fibrosis News From Medical News Today In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 – 23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug development, research and care…
Oct
19 2010
--
Impaired Metabolism In Cystic Fibrosis Lung Epithelial Cells Revealed By Metabolic AnalysisOriginally posted in Cystic Fibrosis News From Medical News Today Metabolon, Inc., the leader in global metabolomics, biomarker discovery and analysis, announces the publication of “Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells”, in the Journal of Biological Chemistry (2010, Vol. 285, No. 40, Pages)…
Oct
14 2010
--
One Step Closer To A Drug Treatment For Cystic Fibrosis, MU Professor SaysOriginally posted in Cystic Fibrosis News From Medical News Today A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world’s most common fatal genetic diseases. The Journal of Biological Chemistry has published findings by Tzyh-Chang Hwang, a professor in the School of Medicine’s Department of Medical Pharmacology and Physiology and the Dalton Cardiovascular Research Center…
Oct
09 2010
--
Researchers Discover 'Walking' Properties Of BacteriaOriginally posted in Cystic Fibrosis News From Medical News Today Talk about a walk on the wild side: University of Notre Dame researcher Joshua Shrout is co-author of a new paper that shows that bacteria are capable of “standing up” and moving while vertical. Shrout, assistant professor of civil engineering and geological sciences and a member of the Eck Institute for Global Health, has been studying the surface motility of bacteria since 2004…
Oct
05 2010
--
Human Growth Hormone Shows Promise In Treating Cystic Fibrosis SymptomsOriginally posted in Cystic Fibrosis News From Medical News Today Human growth hormone can be used successfully to treat some symptoms of cystic fibrosis, but its impact on the disease itself remains unknown, according to a new report funded by HHS’ Agency for Healthcare Research and Quality (AHRQ)…
Oct
04 2010
--
Identification Of A New Bacterial Foe In Cystic FibrosisOriginally posted in Cystic Fibrosis News From Medical News Today Exacerbations in cystic fibrosis (CF) may be linked to chronic infection with a bacterium called Stenotrophomonas maltophilia, which was previously thought to simply colonize the CF lung. The finding that chronic infection with S…
|
|
by Raelene
